The crystal structure of Shiga toxin type 2 with bound disaccharide guides the design of a heterobifunctional toxin inhibitor

Journal of Biological Chemistry

Volumn 289, Issue 2, 2014, Pages 885-894

  Jacobson, Jared M ^a   Yin, Jiang ^b   Kitov, Pavel I ^a   Mulvey, George ^c   Griener, Tom P ^c   James, Michael N G ^b   Armstrong, Glen ^c   Bundle, David R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL OUTCOME; E. COLI; PRIMARY BINDING SITES; SHIGA TOXIN; SHIGA-LIKE TOXINS; STRUCTURAL ELEMENTS;

ESCHERICHIA COLI;

TOXIC MATERIALS;

AMYLOID P COMPONENT; DISACCHARIDE; VEROTOXIN 2;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; IN VITRO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHIGATOXEMIA; TOXEMIA; TOXIN ANALYSIS; TOXIN STRUCTURE;

BACTERIAL TOXINS; CARBOHYDRATE BINDING PROTEIN; CARBOHYDRATE GLYCOCONJUGATE; GLYCOBIOLOGY; GLYCOCONJUGATE; X-RAY CRYSTALLOGRAPHY;

ANIMALS; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; CRYSTALLOGRAPHY, X-RAY; DISACCHARIDES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; LIGANDS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SHIGA TOXIN 2; SURVIVAL ANALYSIS; TOXEMIA;

EID: 84891911695     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.518886     Document Type: Article

References (48)

1. Nataro, J. P., and Kaper, J. B. (1998) Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 11, 142-201
2. Karmali, M. A., Petric, M., Lim, C., Fleming, P. C., Arbus, G. S., and Lior, H. (1985) The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151, 775-782
3. Tarr, P. I., Gordon, C. A., and Chandler, W. L. (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365, 1073-1086
4. Endo, Y., Mitsui, K., Motizuki, M., and Tsurugi, K. (1987) The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J. Biol. Chem. 262, 5908-5912
5. Falguières, T., Mallard, F., Baron, C., Hanau, D., Lingwood, C., Goud, B., Salamero, J., and Johannes, L. (2001) Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol. Biol. Cell 12, 2453-2468
6. Obrig, T. G., Moran, T. P., and Brown, J. E. (1987) The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem. J. 244, 287-294
7. Jackson, M. P., Neill, R. J., O'Brien, A. D. Holmes, R. K., and Newland, J. W. (1987) Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933. FEMS Microbiol. Lett. 44, 109-114
8. Muniesa, M., Hammerl, J. A., Hertwig, S., Appel, B., and Brüssow, H. (2012) Shiga toxin-producing Escherichia coli O104:H4. A new challenge for microbiology. Appl. Environ. Microbiol. 78, 4065-4073
9. Rojas, R. L., Gomes, P. A., Bentancor, L. V., Sbrogio-Almeida, M. E., Costa, S. O., Massis, L. M., Ferreira, R. C., Palermo, M. S., and Ferreira, L. C. (2010) Salmonella enterica serovar typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli. Clin. Vaccine Immunol. 17, 529-536
10. Rutjes, N. W., Binnington, B. A., Smith, C. R., Maloney, M. D., and Lingwood, C. A. (2002) Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 62, 832-845
11. Boerlin, P., McEwen, S. A., Boerlin-Petzold, F., Wilson, J. B., Johnson, R. P., and Gyles, C. L. (1999) Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J. Clin. Microbiol. 37, 497-503
12. Orth, D., Grif, K., Khan, A. B., Naim, A., Dierich, M. P., and Würzner, R. (2007) The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn. Microbiol. Infect. Dis. 59, 235-242
13. St Hilaire, P. M., Boyd, M. K., and Toone, E. J. (1994) Interaction of the Shiga-like toxin type 1 B-subunit with its carbohydrate receptor. Biochemistry 33, 14452-14463
14. Stein, P. E., Boodhoo, A., Tyrrell, G. J., Brunton, J. L., and Read, R. J. (1992) Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature 355, 748-750
15. Shimizu, H., Field, R. A., Homans, S. W., and Donohue-Rolfe, A. (1998) Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry 37, 11078-11082
16. Kitova, E. N., Kitov, P. I., Bundle, D. R., and Klassen, J. S. (2001) The observation of multivalent complexes of Shiga-like toxin with globotriaoside and the determination of their stoichiometry by nanoelectrospray Fourier-transform ion cyclotron resonance mass spectrometry. Glycobiology 11, 605-611
17. Fraser, M. E., Fujinaga, M., Cherney, M. M., Melton-Celsa, A. R., Twiddy, E. M., O'Brien, A. D., and James, M. N. (2004) Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J. Biol. Chem. 279, 27511-27517
18. Kitova, E. N., Kitov, P. I., Paszkiewicz, E., Kim, J., Mulvey, G. L., Armstrong, G. D., Bundle, D. R., and Klassen, J. S. (2007) Affinities of Shiga toxins 1 and 2 for univalent and oligovalent Pk-trisaccharide analogs measured by electrospray ionization mass spectrometry. Glycobiology 17, 1127-1137
19. Mammen, M., Choi, S. K., and Whitesides, G. M. (1998) Polyvalent interactions in biological systems. Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. Engl. 37, 2754-2794
20. Kitov, P. I., Sadowska, J. M., Mulvey, G., Armstrong, G. D., Ling, H., Pannu, N. S., Read, R. J., and Bundle, D. R. (2000) Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403, 669-672
21. Kitov, P. I., and Bundle, D. R. (2003) On the nature of the multivalency effect. A thermodynamic model. J. Am. Chem. Soc. 125, 16271-16284
22. Nishikawa, K., Watanabe, M., Kita, E., Igai, K., Omata, K., Yaffe, M. B., and Natori, Y. (2006) A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin. FASEB J. 20, 2597-2599
23. Watanabe-Takahashi, M., Sato, T., Dohi, T., Noguchi, N., Kano, F., Murata, M., Hamabata, T., Natori, Y., and Nishikawa, K. (2010) An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin. Infect. Immun. 78, 177-183
24. Armstrong, G. D., Fodor, E., and Vanmaele, R. (1991) Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. J. Infect. Dis. 164, 1160-1167
25. Paton, A. W., Morona, R., and Paton, J. C. (2006) Designer probiotics for prevention of enteric infections. Nat. Rev. Microbiol. 4, 193-200
26. Matsuoka, K., Terabatake, M., Esumi, Y., Terunuma, D., and Kuzuhara, H. (1999) Synthetic assembly of trisaccharide moieties of globotriaosyl ceramide using carbosilane dendrimers as cores. A new type of functional glyco-material. Tetrahedron Lett. 40, 7839-7842
27. Nishikawa, K., Matsuoka, K., Kita, E., Okabe, N., Mizuguchi, M., Hino, K., Miyazawa, S., Yamasaki, C., Aoki, J., Takashima, S., Yamakawa, Y., Nishijima, M., Terunuma, D., Kuzuhara, H., and Natori, Y. (2002)Atherapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc. Natl. Acad. Sci. U.S.A. 99, 7669-7674
28. Nishikawa, K., Matsuoka, K., Watanabe, M., Igai, K., Hino, K., Hatano, K., Yamada, A., Abe, N., Terunuma, D., Kuzuhara, H., and Natori, Y. (2005) Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J. Infect. Dis. 191, 2097-2105
29. Watanabe, M., Igai, K., Matsuoka, K., Miyagawa, A., Watanabe, T., Yanoshita, R., Samejima, Y., Terunuma, D., Natori, Y., and Nishikawa, K. (2006) Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues. Infect. Immun. 74, 1984-1988
30. Solomon, D., Kitov, P. I., Paszkiewicz, E., Grant, G. A., Sadowska, J. M., and Bundle, D. R. (2005) Heterobifunctional multivalent inhibitor-adaptor mediates specific aggregation between Shiga toxin and a pentraxin. Org. Lett. 7, 4369-4372
31. Kitov, P. I., Lipinski, T., Paszkiewicz, E., Solomon, D., Sadowska, J. M., Grant, G. A., Mulvey, G. L., Kitova, E. N., Klassen, J. S., Armstrong, G. D., and Bundle, D. R. (2008) An entropically efficient supramolecular inhibition strategy for Shiga toxins. Angew. Chem. Int. Ed. Engl. 47, 672-676
32. Kitov, P. I., Mulvey, G. L., Griener, T. P., Lipinski, T., Solomon, D., Paszkiewicz, E., Jacobson, J. M., Sadowska, J. M., Suzuki, M., Yamamura, K., Armstrong, G. D., and Bundle, D. R. (2008) In vivo supramolecular templating enhances the activity of multivalent ligands. A potential therapeutic against the Escherichia coli O157 AB(5) toxins. Proc. Natl. Acad. Sci. U.S.A. 105, 16837-16842
33. Flagler, M. J., Mahajan, S. S., Kulkarni, A. A., Iyer, S. S., and Weiss, A. A. (2010) Comparison of binding platforms yields insights into receptor binding differences between Shiga toxins 1 and 2. Biochemistry 49, 1649-1657
34. Kale, R. R., McGannon, C. M., Fuller-Schaefer, C., Hatch, D. M., Flagler, M. J., Gamage, S. D., Weiss, A. A., and Iyer, S. S. (2008) Differentiation between structurally homologous Shiga 1 and Shiga 2 toxins by using synthetic glycoconjugates. Angew. Chem. Int. Ed. Engl. 47, 1265-1268
35. Jacobson, J. M., Kitov, P. I., and Bundle, D. R. (2013) The synthesis of a multivalent heterobifunctional ligand for specific interaction with Shiga toxin 2 produced by E. coli O157:H7. Carbohydr. Res. 378, 4-14
36. Otwinowski, Z., and Minor, W. (1997) Methods Enzymol.: Macromolecular Crystallography Part A (Carter, C. W., Jr., and Sweet, R. M., eds.) pp. 307-326, Academic Press, New York
37. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674
38. McRee, D. E. (1999) XtalView/Xfit. A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125, 156-165
39. Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F., and Vagin, A. A. (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367
40. Langer, G., Cohen, S. X., Lamzin, V. S., and Perrakis, A. (2008) Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. Nat. Protoc. 3, 1171-1179
41. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) PROCHECK. A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283-291
42. Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010) MolProbity. All-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21
43. Zhao, X., Araki, K., Miyazaki, J., and Yamamura, K. (1992) Developmental and liver-specific expression directed by the serum amyloid P component promoter in transgenic mice. J. Biochem. 111, 736-738
44. Armstrong, G. D., Mulvey, G. L., Marcato, P., Griener, T. P., Kahan, M. C., Tennent, G. A., Sabin, C. A., Chart, H., and Pepys, M. B. (2006) Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo. Therapeutic implications for hemolytic-uremic syndrome. J. Infect. Dis. 193, 1120-1124
45. Griener, T. P., Strecker, J. G., Humphries, R. M., Mulvey, G. L., Fuentealba, C., Hancock, R. E., and Armstrong, G. D. (2011) Lipopolysaccharide renders transgenic mice expressing human serum amyloid P component sensitive to Shiga toxin 2. PLoS ONE 6, e21457
46. Snedeker, K. G., Shaw, D. J., Locking, M. E., and Prescott, R. J. (2009) Primary and secondary cases in Escherichia coli O157 outbreaks. A statistical analysis. BMC Infect. Dis. 9, 144
47. Hong, S. W., Lee, B. S., Park, S. J., Jeon, H. R., Moon, K. Y., Kang, M. H., Park, S. H., Choi, S.-U., Song, W. H., Lee, J., and Choi, Y. W. (2011) Solid dispersion formulations of megestrol acetate with copovidone for enhanced dissolution and oral bioavailability. Arch. Pharmacal. Res. 34, 127-135
48. Dasgupta, S., Kitov, P. I., Sadowska, J. M., and Bundle, D. R. (2013) Discovery of inhibitors of Shiga toxin type 2 by on-plate generation and screening of a focused compound library. Angew. Chem. Int. Ed. Engl., doi. 10.1002/anie.201309436